Policy Watch: 20 Regulatory Updates — May 13, 2026
Policy WatchMay 13, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I don't see an article…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyMental Health Clinical Summary The Drug Enforcement…
Policy Watch: 10 Regulatory Updates — April 12, 2026
Policy WatchApril 12, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 10 Regulatory Updates — April 01, 2026
Policy WatchApril 01, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I don't see an article…
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters I don’t see a summary…
Definition of Engaged in the Business as a Dealer in Firearms
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicyIndustry Dr. Caplan’s Take I appreciate the prompt, but I notice the article title and…
Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters I don’t see a summary…